Share Name Share Symbol Market Type Share ISIN Share Description
Reneuron Group LSE:RENE London Ordinary Share GB00B0DZML60 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.05p +2.33% 2.20p 2.10p 2.30p 2.20p 2.15p 2.15p 979,025.00 11:08:50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -12.8 -0.4 - 69.50

Reneuron Share Discussion Threads

Showing 13851 to 13873 of 13875 messages
Chat Pages: 555  554  553  552  551  550  549  548  547  546  545  544  Older
DateSubjectAuthorDiscuss
26/4/2017
15:30
Think I may take the plunge and buy some of these. Could be a stressful journey but nothing ventured and all that...
audigger
25/4/2017
12:14
;-) Like that. I ran it past a well known Ophtha friend of mine and he said it could do very well, but its a punt. Figured, with the other products it has to, why not.
dennisbergkamp
25/4/2017
10:57
Interesting list of posts. I cannot quite understand the drift but... Best wishes to all. Freddie
fredd1eboy
25/4/2017
10:52
Welcome on board buddy. Your as equally stupid as I am
yachtmaster2
25/4/2017
10:20
Right, I'm in... Lets roll!
dennisbergkamp
24/4/2017
21:16
"NOMADS have NO integrity; They suck blood and fees, stifeling the PIs" Poor grammar and an even worse attempt at a pun.
rotors
24/4/2017
09:59
NOMADS have NO integrity; They suck blood and fees, stifeling the PIs
norbus
21/4/2017
17:17
Just to advise further that Stifel is RENE's NOMAD. So they either have the inside track or a motive. Cav Emp.
rotors
21/4/2017
16:55
Stifel Target price 15p 'We value ReNeuron using a risk-adjusted NPV, suggesting a target price of 15p. This places no value on the CRD or exosome programmes – the exosome platform in particular is an exciting new therapy field where ReNeuron is leading development, and is thus likely to represent significant upside to our valuation in the event of a deal or positive clinical trial results. Risk to our investment case include clinical trial delays or negative clinical trial results. ReNeuron will also be reliant on funding or partnership deals once its current cash has expired in 2H18.'
rotors
21/4/2017
16:39
Guess you will have to look up Reneuron on either lse or iii sites to watch the proactive micheal hunt interview
fredd1eboy
21/4/2017
16:38
try again [...]
fredd1eboy
21/4/2017
16:36
Micheal Hunt interview c/o mol iii site [...]
fredd1eboy
21/4/2017
11:36
Goo news.....Motley Fool update...c/o oil prince iii site http://www.fool.co.uk/investing/2017/04/21/this-neil-woodford-favourite-looks-attractive-after-q4-update/
fredd1eboy
21/4/2017
08:44
Shareholders have to keep the pressure on the management to keep it as honest as a man with previous form can be to avoid selling the company cheap having been derisked if they get there, with your money Market not impressed
norbus
21/4/2017
08:31
Yes, there's a pulse.
dogwalker
21/4/2017
07:47
Good news.
small crow
20/4/2017
14:09
Thank you for your email and for your support as a shareholder of ReNeuron. ReNeuron is aware of the video posted on social media and can confirm that the company was not involved in making it or had prior knowledge of its publication. ReNeuron is the sponsor of the Phase I/II clinical trial in RP, a role in which it provides the drug product and finances the trial but is not directly involved with study participants. Whilst it isn’t appropriate for ReNeuron to comment on the content of the video, please rest assured that ReNeuron will announce clinical data from the RP study, and other clinical programmes, in a timely manner through the conventional regulatory channel of RNS. I would make the general point that the results of clinical trials are based on statistical analysis of all patients that complete a trial. A single patient, even in a small study, is not necessarily representative of the overall study results - that could only be known in hindsight. All trials, even late stage ones, have non-responders to the potential treatment being studied. A further general point on early stage trials is that they are designed to inform later studies by establishing safety, tolerability and frequently dosage. For example, the Phase II part of the current Phase I/II trial in RP will be conducted at the highest safe dose in RP patients with a greater level of vision.
fredd1eboy
20/4/2017
13:44
where is the video? If it were misleading they would have gone to court to take it off circulation. The reply is significant. No denial ,disassociation with no defence. BAD
norbus
20/4/2017
09:38
The same applies to you too, stevedd. The answer to your question is 'yes they do'.
dogwalker
20/4/2017
09:36
Why do you ask stewart_25? Haven't you written your money off on this one yet? But, if you really need to know, why not read some of the preceeding posts which people have helpfully contributed here?
dogwalker
20/4/2017
09:22
what is with the video? content? impact on rene?
stewart_25
20/4/2017
09:18
Somebody is systematically ditching big lumps. Its been going on for a while. I hope the Bod are not being complicit in their silence!
deutsch3
20/4/2017
08:22
I haven't heard of this video. Does anybody have a link or an overview of the content?
stevedd
Chat Pages: 555  554  553  552  551  550  549  548  547  546  545  544  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:34 V: D:20170428 23:46:16